We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

ACG 2025

Advertisement

cGxPJobs Banner

TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen

Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...

By cGxPwire Editor
October 27, 2025

Read More

Advertisement

cGxPJobs

Recent Posts

01

Bio-Pharma

Kali Therapeutics Wins FDA Clearance for KT501 IND
September 4, 2026
02

Pharma

Eisai and Biogen Win China Approval for LEQEMBI SC
September 4, 2026
03

.Clinical

Alpha Tau Completes IMPACT Pancreatic Cancer Enrollment
September 4, 2026
04

MedTech

Pulnovo Medical Reports PADN Trial Results in NEJM
September 4, 2026
05

MedTech

Autonomix Medical Presents Nerve Technology at CIRSE 2026
September 4, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website